CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4.5%

CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded down 4.5% during trading on Monday . The stock traded as low as $47.86 and last traded at $48.32. 483,014 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 1,146,552 shares. The stock had previously closed at $50.58.

Analyst Ratings Changes

Several analysts have issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $88.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, August 8th. Citigroup raised CRISPR Therapeutics from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a research report on Thursday, August 17th. Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $123.00 to $110.00 and set a “buy” rating for the company in a report on Monday, August 7th. StockNews.com started coverage on shares of CRISPR Therapeutics in a research report on Thursday, August 17th. They issued a “sell” rating for the company. Finally, Morgan Stanley boosted their price target on shares of CRISPR Therapeutics from $42.00 to $43.00 and gave the stock an “underweight” rating in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $70.94.

CRISPR Therapeutics Trading Down 5.6 %

The firm has a fifty day moving average price of $52.39 and a 200-day moving average price of $53.43.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 7th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($2.13) by $1.15. CRISPR Therapeutics had a negative net margin of 240.84% and a negative return on equity of 21.85%. The company had revenue of $70.00 million during the quarter, compared to analysts’ expectations of $1.80 million. During the same period in the previous year, the company earned ($2.40) EPS. The business’s revenue for the quarter was up 34900.0% compared to the same quarter last year. Research analysts anticipate that CRISPR Therapeutics AG will post -4.97 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CRSP. ARK Investment Management LLC lifted its stake in CRISPR Therapeutics by 2.0% in the 1st quarter. ARK Investment Management LLC now owns 7,990,188 shares of the company’s stock valued at $361,396,000 after purchasing an additional 160,256 shares during the last quarter. Capital International Investors lifted its stake in shares of CRISPR Therapeutics by 0.8% in the 2nd quarter. Capital International Investors now owns 6,069,723 shares of the company’s stock valued at $340,754,000 after acquiring an additional 46,085 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of CRISPR Therapeutics by 158.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company’s stock valued at $183,194,000 after acquiring an additional 1,848,437 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in CRISPR Therapeutics by 33.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,993,577 shares of the company’s stock worth $121,689,000 after purchasing an additional 752,132 shares in the last quarter. Finally, BlackRock Inc. raised its position in CRISPR Therapeutics by 6.4% in the first quarter. BlackRock Inc. now owns 2,798,581 shares of the company’s stock valued at $126,580,000 after purchasing an additional 168,844 shares during the last quarter. Institutional investors own 68.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.